SCHEMBL309609

SCHEMBL309609

FC(F)(F)[C@H]1CO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL151485 1.00
SCHEMBL690652 1.00
SCHEMBL20403353 0.96
SCHEMBL11215861 0.78 CHRM2 (0.32)
SCHEMBL6239745 0.72
SCHEMBL6382829 0.72
SCHEMBL6385694 0.72
SCHEMBL8927903 0.72
SCHEMBL11387395 0.72
SCHEMBL12497230 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 322 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122029147-A Probes for MAGL 豪夫迈·罗氏有限公司 2026-05-12 CN disclosed
US-20260116885-A1 ION CHANNEL MODULATORS PRAXIS PREC MEDICINES INC (US) 2026-04-30 US disclosed
EP-4688792-A1 KRAS INHIBITORS Eli Lilly and Company (US) 2026-02-11 EP disclosed
EP-4688156-A1 LACTAM-CONTAINING IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS Janssen Pharmaceutica NV (BE) 2026-02-11 EP disclosed
US-12540157-B2 Oxysterols and methods of use thereof Sage Therapeutics, LLC (US) 2026-02-03 US disclosed
WO-2025262243-A1 THIENO- AND THIAZOLOPYRIMIDINE-2,6-DIONES AND USE THEREOF AS IMMUNOMODULATORS INVIOS GMBH (AT) 2025-12-26 WO disclosed
US-20250325550-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS INCYTE CORP (US) 2025-10-23 US disclosed
US-20250289823-A1 USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS INCYTE CORPORATION 2025-09-18 US disclosed
US-12344615-B2 Substituted pyridines as ion channel modulators PRAXIS PRECISION MEDICINES, INC. (US) 2025-07-01 US disclosed
US-20250171427-A1 THERAPEUTIC COMPOUNDS SANOFI (FR) 2025-05-29 US disclosed
US-6677341-B2 USEFUL FOR TREATING ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASE;REACTING AN AMINE COMPOUND WITH AN EPOXIDE DERIVATIVE IN PRESENCE OF TRANSITION METAL SALT CATALYST PHARMACIA CORPORATION 2004-01-13 US disclosed
US-20030078264-A1 (R)-chiral halogenated substituted N,N-bis-benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity SIKORSKI JAMES A (US) 2003-04-24 US disclosed
US-6544974-B2 Treating atherosclerosis and other coronary artery diseases. G.D. SEARLE & CO. 2003-04-08 US disclosed
US-20030050317-A1 (R)-chiral halogenated substituted n,n-bis-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity SIKORSKI JAMES A (US) 2003-03-13 US disclosed
US-20030040545-A1 (R)-Chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesteryl ester transfer protein activity SIKORSKI JAMES A (US) 2003-02-27 US disclosed
US-6521607-B1 Preventing coronary artery disease PHARMACIA CORPORATION 2003-02-18 US disclosed
US-20030027826-A1 (R)-Chiral halogenated substituted heteroaryl benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity SIKORSKI JAMES A (US) 2003-02-06 US disclosed
US-20020177708-A1 (R)-chiral halogenated substituted N-benzyl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity SIKORSKI JAMES A (US) 2002-11-28 US disclosed
EP-1115695-A1 (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(N+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY Monsanto Company (US) 2001-07-18 EP disclosed
WO-2000018724-A1 (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(n+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY MONSANTO COMPANY (US) 2000-04-06 WO disclosed